Latest News

With midterm elections near, PhRMA continues to spend


 

The Pharmaceutical Research and Manufacturers of America (PhRMA) continued to lead the health sector in lobbying spending through the third quarter of 2018, according to the Center for Responsive Politics.

Highest-spending lobbyers through third quarter, 2018

PhRMA’s $21.8 million worth of lobbying through September put it ahead of Blue Cross Blue Shield’s $17.2 million. PhRMA remains on pace to exceed its previous spending high of $27.2 million in 2009, and the health sector as a whole, with a lobbying bill of $421.5 million for three-quarters of 2018, is just slightly ahead of last year’s record of $561.3 million, the center reported on OpenSecrets.org.

PhRMA is third overall in lobbying spending so far this year, behind the U.S. Chamber of Commerce ($69.1 million) and the National Association of Realtors ($53.8 million). Blue Cross Blue Shield is sixth overall, with the American Hospital Association ($17.2 million, seventh) and the American Medical Association ($15.5 million, ninth) also in the top 10, according to the center’s analysis of data from the Senate Office of Public Records.

The pharmaceutical/health product industry leads health-sector lobbying with $216.1 million in spending so far in 2018, followed by hospitals/nursing homes at $73.6 million, health professionals at $68.6 million, and health services/HMOs at $57.5 million.

Recommended Reading

FDA offers guidance on MRD assessment in blood cancer trials
MDedge Hematology and Oncology
TV ads must trumpet drug prices, Trump administration says. Pharma tries a Plan B.
MDedge Hematology and Oncology
The Sunshine Act, 5 years hence
MDedge Hematology and Oncology
States act to safeguard young cancer patients’ chances to have children
MDedge Hematology and Oncology
Kymriah appears cost effective in analysis
MDedge Hematology and Oncology
Study: Problems persist with APMs
MDedge Hematology and Oncology
Booming economy helps flatten Medicaid enrollment and limit costs, states report
MDedge Hematology and Oncology
Experts: Kavanaugh may have lasting impact on health care
MDedge Hematology and Oncology
Trump scheme for Part B drugs raises red flags
MDedge Hematology and Oncology
With one hand, administration boosts ACA marketplaces, weakens them with another
MDedge Hematology and Oncology